FeesSafety
Pluang+

Orion Energy Systems to present at Southwest IDEAS Investor Conference on Nov 18 in Dallas.

Market News
04 Nov 2026, 15:28 WIB
GlobeNewsWire
View Source
Neutral
Orion Energy Systems to present at Southwest IDEAS Investor Conference on Nov 18 in Dallas.

Orion Energy Systems announced that CEO Sally Washlow and CFO Per Brodin will present at the Southwest IDEAS Investor Conference on November 18, 2026, in Dallas, Texas. The presentation will be webcast and accessible via the conference and company websites. This event offers Orion a platform to showcase its energy efficiency and clean technology solutions to investors, potentially boosting visibility and investor interest. The IDEAS Conference is known for connecting quality companies with regional investment professionals.

Orion Energy Systems' upcoming presentation at the Southwest IDEAS Investor Conference provides context for industrial sector activity on Pluang. For readers following Industrials, here is Pluang's market snapshot as of Nov 04, 2026 20:11 WIB: Among 136 priced US Industrials stocks, 72 rose and 57 fell today. Notable movers include GEO at USD 26.12 with a 1-day change of -6.93%, VRT at USD 220.00 down 6.77%, and POWL at USD 152.83 down 6.43%. Typical hold times range from 9 to 45 days, with varying Pluang order activity percentages.

More News

Good Life Meds must stop unproven health and personalization claims for compounded Tirzepatide+ products.

Good Life Meds must stop unproven health and personalization claims for compounded Tirzepatide+ products.

The National Advertising Division (NAD) recommended that Good Life Meds discontinue claims about health benefits and personalization for its compounded Tirzepatide+ weight loss products after a challenge by Eli Lilly. NAD found that Good Life lacked ...

Market News
Bearish
26 minutes ago
Moleculin's Annamycin shows promising remission rates in AML trial, data to be presented at ASH 2026.

Moleculin's Annamycin shows promising remission rates in AML trial, data to be presented at ASH 2026.

Moleculin Biotech announced that interim results from its Phase 2/3 trial of Annamycin for relapsed or refractory acute myeloid leukemia (AML) will be presented at the 2026 ASH Annual Meeting. The trial showed remission rates of 43% and 36% in two An...

Company Fundamentals
Bullish
26 minutes ago
ANZ dental implants market to grow 5% CAGR, reaching $393M by 2033 driven by aging population and prosthetic demand

ANZ dental implants market to grow 5% CAGR, reaching $393M by 2033 driven by aging population and prosthetic demand

The Australia and New Zealand (ANZ) dental implants market, valued at $266 million in 2025, is projected to grow at a 5% CAGR to $393 million by 2033. Growth is driven by increasing demand for oral rehabilitation and prosthetic dentistry, especially ...

Market News
Bullish
26 minutes ago
New study shows Asgard's tech induces cancer-fighting structures in tumors, boosting therapy success across 7 cancer types.

New study shows Asgard's tech induces cancer-fighting structures in tumors, boosting therapy success across 7 cancer types.

Asgard Therapeutics published a study in Immunity demonstrating its technology can reprogram tumor cells into dendritic cells, inducing cancer-fighting tertiary lymphoid structures (imgTLSs) across seven tumor types. This tumor-agnostic approach led ...

Others
Bullish
26 minutes ago
Cap expands onchain credit marketplace to finance film production without tokenizing assets

Cap expands onchain credit marketplace to finance film production without tokenizing assets

Cap, an onchain credit marketplace, is expanding into film and media financing by providing funding for the upcoming film Wake. This deal uses advances against anticipated film production tax credits, showing how Cap's underwriting model supports spe...

Market News
Bullish
26 minutes ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App